omeprazole+domperidone SR; omeprazole
Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза IV — препарат уже зарегистрирован. Собирают дополнительные сведения о пользе и безопасности при обычном применении.
- Статус исследования в реестре не указан — уточняйте в центре.
- Возраст участников: 18–70 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 60 чел. во всех странах исследования.
- Центров в реестре: 2 в одном городе. Список — ниже на странице.
- Плановая дата окончания (06.2014) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 32
Критерии включения
- Criteria of inclusion of subjects
- desire to participate in the trial and ability to sign the informed consent;
- age above 18;
- gastroesophageal reflux disease, manifested in heartburn no less than twice a week prior to the 1st visit;
- use for the trial period of safe contraception methods for women of fertile age;
- results of ultrasonography (US) of abdominal cavity organs (ACO) performed in the last 6 months before the enrollment.
- Criteria of non-inclusion refusal to undergo the endoscopic examination;
- gastroesophageal reflux disease with severe esophagitis (grade С or D against the Los Angeles classification);
- Barrett esophagus;
- pregnancy or lactation;
- administration of nonsteroidal antiinflammatory drugs (NSAIDs), aspirin, bisphosphonates, nitrates, calcium antagonists, proton pump inhibitors or Н2-blockers, prokinetics, clopidogrel;
- participation in other clinical trial;
- history of allergic reaction or intolerance of components of medicinal products;
- esophageal stricture;
- gastrectomy or gastric resection;
- malignant neoplasms in any location at present;
- alcohol abuse;
- severe cardiovascular or respiratory insufficiency;
- hepatic insufficiency;
- renal insufficiency.
- Criteria of exclusion
- investigator's opinion on the necessity to exclude the patient for their own benefit;
- erroneous enrollment;
- investigator's decision to exclude the patient due to serious deviation from the trial program;
- serious adverse events (SAEs) including death (stating the date of death);
- adverse events (AEs) requiring monitoring and drug therapy;
- acute diseases or conditions which in the investigator's opinion require the patient to be excluded from the trial;
- administration during the trial of NSAIDs, aspirin, bisphosphonates, nitrates, calcium antagonists, proton pump inhibitors or Н2-blockers, prokinetics, antacids (except for the tested MP or the comparator MP) or the necessity for such treatment to be prescribed;
- positive pregnancy test (for women);
- patient's failure to appear for the visit;
- patient's refusal to continue the trial;
- intolerance of the tested MP or the comparator MP;
Источник: ClinicalTrials.gov, NCT02140073 · запись обновлена в реестре 16 мая 2014.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 3
- change incidence of heartburn after 8 weeks of treatment with Omez-DSR preparation in comparison with OMEZ preparation — change from baseline incidence of heartburn after 8 weeks of treatment
- change severity of heartburn after 8 weeks of treatment with Omez-DSR preparation in comparison with OMEZ preparation — change from baseline severity of heartburn at 8 weeks
Цель исследования
The purpose of this study is to determine the efficacy, safety, and tolerability of omeprazole in combination with domperidone in GERD treatment for subsequent efficient pharmacotherapy of GERD.
Objectives of the trial To assess the efficacy of omeprazole in combination with domperidone regarding change of incidence and severity of clinical symptoms of GERD during 8 weeks of treatment To compare the efficacy of omeprazole in combination with domperidone regarding change of incidence and severity of clinical symptoms of GERD during 8 weeks of treatment To assess the efficacy of omeprazole in combination with domperidone regarding change of incidence and severity of endoscopic symptoms of GERD during 8 weeks of treatment To compare the efficacy of omeprazole in combination with domperidone regarding change of incidence and severity of endoscopic symptoms of GERD during 8 weeks of treatment To determine the efficiency and advantages of one GERD therapy considering efficacy, safety, and individual variance of patients' reactions
Где проходит
2 центра в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02140073 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.